Lancet:脉搏血氧饱和度监测联合临床评估适用于中国新生儿先天性心脏病筛查

2014-05-04 艾兰博曼 艾兰博曼

由复旦大学附属儿科医院心内科专家黄国英教授、贾兵教授执导的一项前瞻性研究表明,在中国,脉搏血氧饱和度监测联合临床评估用于检查新生儿先天性心脏病是可行、可靠的。该研究成果发表于2014年4月23日的 The Lancet。研究人员对上海的三家医院进行了初步研究,评估脉搏血氧饱和度监测联合临床评估筛查先天性心脏病的准确性。在征集新病例前,研究人员制定了数据收集计划,随后进行了一项大型的、前瞻性的、多中

由复旦大学附属儿科医院心内科专家黄国英教授、贾兵教授执导的一项前瞻性研究表明,在中国,脉搏血氧饱和度监测联合临床评估用于检查新生儿先天性心脏病是可行、可靠的。该研究成果发表于2014年4月23日的 The Lancet。

研究人员对上海的三家医院进行了初步研究,评估脉搏血氧饱和度监测联合临床评估筛查先天性心脏病的准确性。在征集新病例前,研究人员制定了数据收集计划,随后进行了一项大型的、前瞻性的、多中心筛查研究,筛查了2011年8月1日到2012年11月30日在中国18家医院连续出生的所有新生儿(年龄6-72 小时)。筛查后24小时内,阳性筛查结果的新生儿(异常的脉搏血氧饱和度测定值或异常的临床评估)被送去检查超声心动图,并通过临床随访和家长的反馈确定了假阴性结果。研究人员计算了检测主要的和危重的先天性心脏病的敏感性、特异性、阳性和阴性的预测值、单独使用脉搏血氧饱和度监测的阳性和阴性的似然比以及与临床评估相结合的似然比。

该初步研究共筛查了连续出生的6785例新生儿。通过脉搏血氧饱和度监测和临床评估联合筛查,49例中有46例患有无主要的先天性心脏病症状的(94%),另8例全部(100%)患有无危重病症状的新生儿。在前瞻性多中心研究中,研究人员筛查了连续出生的122738例新生儿(120707例无症状,2031例有症状),检测到1071例先天性心脏病(危重的157例,主要的330例)。在无症状的新生儿中,脉搏血氧饱和度监测联合临床评估的灵敏度,危重先天性心脏病是93.2 %(95% CI:87.9-96.2),主要疾病是90.2 %(86.4-93.0)。临床评估附加脉搏血氧饱和度监测将检测危重先天性心脏病的灵敏度从77.4 %(95% CI:70.0-83.4)提高到93.2%(87.9-96.2)。检测危重疾病的假阳性率,单独采用临床评估是2.7 %(120392例中3298例),单独采用脉搏血氧饱和度监测是0.3 %(120561例中394例)。

此前,一些开拓性研究已经为采用通用的脉搏血氧饱和度监测筛查危重先天性心脏病提供了证据。然而,高收入国家研究报道的成功筛查是否在低收入国家也会获得相似的成效尚不可知。本次研究结果证实,脉搏血氧饱和度监测联合临床评估用于筛查中国新生儿先天性心脏病是可行、可靠的。同时,该研究建议妇产医院应该推广这个简单、准确的联合方法来筛查先天性心脏病。


Lancet同期刊登的英国学者Andrew K Ewer的评论文章中指出,这是首次在发展中国家证明了开展新生儿先心病筛查的可行性和可靠性,同时也是目前为止全球范围内样本量最大的研究(129523名新生儿),为世界进一步推广新生儿先心病筛查提供了重要的循证数据。

原始出处:

Zhao QM1, Ma XJ2, Ge XL2, Liu F1, Yan WL2, Wu L1, Ye M1, Liang XC1, Zhang J1, Gao Y1, Jia B3, Huang GY4; the Neonatal Congenital Heart Disease screening group.Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study.Lancet. 2014 Apr 22. pii: S0140-6736(14)60198-7. doi: 10.1016/S0140-6736(14)60198-7. [Epub ahead of print]

Andrew K Ewer.Pulse oximetry screening: do we have enough evidence now?The Lancet April 23 2014 doi:10.1016/S0140-6736(14)60575-4

相关报道:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1740889, encodeId=189b1e40889ef, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Sun Jan 25 12:58:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827788, encodeId=b875182e78807, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 20 18:58:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369188, encodeId=6dae136918882, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378819, encodeId=eec313e881930, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548688, encodeId=c5bf15486880a, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595727, encodeId=0dc21595e27dc, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1740889, encodeId=189b1e40889ef, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Sun Jan 25 12:58:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827788, encodeId=b875182e78807, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 20 18:58:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369188, encodeId=6dae136918882, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378819, encodeId=eec313e881930, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548688, encodeId=c5bf15486880a, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595727, encodeId=0dc21595e27dc, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
    2014-07-20 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1740889, encodeId=189b1e40889ef, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Sun Jan 25 12:58:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827788, encodeId=b875182e78807, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 20 18:58:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369188, encodeId=6dae136918882, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378819, encodeId=eec313e881930, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548688, encodeId=c5bf15486880a, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595727, encodeId=0dc21595e27dc, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
    2014-05-06 huirong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1740889, encodeId=189b1e40889ef, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Sun Jan 25 12:58:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827788, encodeId=b875182e78807, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 20 18:58:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369188, encodeId=6dae136918882, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378819, encodeId=eec313e881930, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548688, encodeId=c5bf15486880a, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595727, encodeId=0dc21595e27dc, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1740889, encodeId=189b1e40889ef, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Sun Jan 25 12:58:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827788, encodeId=b875182e78807, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 20 18:58:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369188, encodeId=6dae136918882, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378819, encodeId=eec313e881930, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548688, encodeId=c5bf15486880a, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595727, encodeId=0dc21595e27dc, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1740889, encodeId=189b1e40889ef, content=<a href='/topic/show?id=9c76230166d' target=_blank style='color:#2F92EE;'>#临床评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23016, encryptionId=9c76230166d, topicName=临床评估)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e55d34837992, createdName=12498dabm88暂无昵称, createdTime=Sun Jan 25 12:58:00 CST 2015, time=2015-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827788, encodeId=b875182e78807, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jul 20 18:58:00 CST 2014, time=2014-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369188, encodeId=6dae136918882, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378819, encodeId=eec313e881930, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548688, encodeId=c5bf15486880a, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595727, encodeId=0dc21595e27dc, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Tue May 06 01:58:00 CST 2014, time=2014-05-06, status=1, ipAttribution=)]
    2014-05-06 lqvr

相关资讯

Int J Cardio:波生坦可治疗唐氏综合征患者的先天性心脏病相关肺动脉高压

口服波生坦对先天性心脏病(CHD)相关的肺动脉高压(PAH)治疗有效,但对唐氏综合征患者的疗效仍然未知。那不勒斯第二大学心血管学院的Michele D’Alto等人对此进行了研究,发现波生坦对于患有唐氏综合征的CHD相关PAH患者同样有效,研究结果发表于《国际心脏病学杂志》。 本次研究的对象为有无唐氏综合征的CHD相关PAH患者,旨在评估波生坦在这两类患者中的长期疗效。对患者基线水平和波生坦治疗

先天性心脏病相关性肺动脉高压诊治专家共识(上)

  随着肺动脉高压(pulmonary arterial hypertension,PAH)研究的深入以及各种靶向治疗药物的问世,PAH诊治已取得长足进展。在我国,先天性心脏病(congenital heartdisease,CHD)是引起PAH最常见原因,诸多患者因PAH而失去手术机会。然而,CHD相关性PAH(PAH associated withCHD,PAH-CHD)如何诊治,目前尚无统一

Am J Cardiol:先心病患者宜用仅含孕酮成分的避孕药

  西班牙一项研究表明,尽管一些患者有禁忌证,但有相当高比例的先天性心脏病(CHD)患者曾应用雌激素孕酮复合避孕药(EPCC),在转至孕前门诊前,CHD患者应用孕酮成分避孕药(PC)比例较低。PC无血栓形成副作用,并且妇产科副作用发生率可接受,值得推广。论文于5月24日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   既往报道显示,CHD患者避孕方法包括EPC

JACC:先心病成年患者NT-proBNP水平与其心功能有关

研究要点:1.研究人员进行了此项研究,旨在评估NT-proBNP对于先心病患者的临床意义,并评估NT-proBNP与先心病患者心脏功能及运动功能之间的关系。2.研究结果显示,NT-proBNP水平因先心病的种类不同而有差异,其中Fontan术后的先心病患者NT-proBNP水平最高,主动脉缩窄患者NT-proBNP水平最低。3.NT-proBNP与患者的超声心动图参数及运动耐力具有相关性。此前有研

Heart Rhythm: ICD放电对成人先天性心脏病患者性功能的影响

随着植入式心脏转复除颤器(ICD)的问世,越来越多的成人先天性心脏病患者植入ICD用于心源性猝死的一级或二级预防,其主要原因包括越来越多的恶性心律失常被发现及ICD技术的日益成熟。法洛氏四联症患者是需要植入ICD的最大亚群,既往的临床研究已经涉及了ICD植入失败及ICD相关并发症的原因分析,约30%-40%的患者存在ICD的不正确放电。 虽然ICD放电可以拯救患者的生命,但是其带来的心理上的影响

EHJ:王红艳等发现MTR基因多态性与先天性心脏病有关

2013年6月,国际著名杂志《欧洲心脏杂志》(European Heart Journal,影响因子14.1)在线发表了复旦大学生命科学学院王红艳课题组的研究论文“Genetic variants reducing MTR gene expression increase risk of congenital heart disease in Han Chinese population”(Zha